These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 32142372)

  • 1. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
    Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Kamide Y; Nakamura Y; Hamada Y; Tomita Y; Sekiya K; Tsuburai T; Izuhara K; Wakahara K; Hashimoto N; Hasegawa Y; Taniguchi M
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1488-1498. PubMed ID: 32142372
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab can inhibit respiratory reaction during aspirin desensitization.
    Lang DM; Aronica MA; Maierson ES; Wang XF; Vasas DC; Hazen SL
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):98-104. PubMed ID: 29777744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab.
    Phillips-Angles E; Barranco P; Lluch-Bernal M; Dominguez-Ortega J; López-Carrasco V; Quirce S
    J Allergy Clin Immunol Pract; 2017; 5(3):842-845. PubMed ID: 28117272
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
    Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A trial of type 12 purinergic (P2Y
    Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
    J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease.
    Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Tomita Y; Kamide Y; Tsuburai T; Sekiya K; Ishii M; Hasegawa Y; Taniguchi M
    J Allergy Clin Immunol; 2023 Jun; 151(6):1667-1672.e2. PubMed ID: 36967017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
    Valero A; Sánchez-López J; Bartra J; Serrano C; Muñoz-Cano R; Roca J; Picado C
    Int Arch Allergy Immunol; 2011; 156(2):221-3. PubMed ID: 21597303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.
    Cahill KN; Cui J; Kothari P; Murphy K; Raby BA; Singer J; Israel E; Boyce JA; Laidlaw TM
    Am J Respir Crit Care Med; 2019 Sep; 200(6):704-711. PubMed ID: 30978291
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
    Quint T; Dahm V; Ramazanova D; Arnoldner MA; Kurz H; Janik S; Brunner PM; Knerer-Schally B; Weninger W; Griss J; Ristl R; Schneider S; Bangert C
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):506-516.e6. PubMed ID: 34678497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease.
    Hayashi H; Mitsui C; Nakatani E; Fukutomi Y; Kajiwara K; Watai K; Sekiya K; Tsuburai T; Akiyama K; Hasegawa Y; Taniguchi M
    J Allergy Clin Immunol; 2016 May; 137(5):1585-1587.e4. PubMed ID: 26559322
    [No Abstract]   [Full Text] [Related]  

  • 11. Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
    Cahill KN; Wu P; Milne GL; Amin T; Singer J; Murphy K; Lewis E; Gapko D; Boyce JA; Buchheit KM; Laidlaw TM
    J Allergy Clin Immunol; 2022 Jul; 150(1):170-177.e6. PubMed ID: 35026207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease.
    Jean T; Eng V; Sheikh J; Kaplan MS; Goldberg B; Jau Yang S; Samant S
    Allergy Asthma Proc; 2019 Sep; 40(5):316-320. PubMed ID: 31514790
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
    Mastalerz L; Januszek R; Kaszuba M; Wójcik K; Celejewska-Wójcik N; Gielicz A; Plutecka H; Oleś K; Stręk P; Sanak M
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt B):163-9. PubMed ID: 26209241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E
    Mastalerz L; Tyrak KE; Ignacak M; Konduracka E; Mejza F; Ćmiel A; Buczek M; Kot A; Oleś K; Sanak M
    Allergy; 2019 May; 74(5):922-932. PubMed ID: 30446997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
    Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
    J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab in the treatment of aspirin-exacerbated respiratory disease.
    Bergmann KC; Zuberbier T; Church MK
    J Allergy Clin Immunol Pract; 2015; 3(3):459-60. PubMed ID: 25648572
    [No Abstract]   [Full Text] [Related]  

  • 17. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
    Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
    J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
    [No Abstract]   [Full Text] [Related]  

  • 18. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
    Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
    J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.
    Tan JHY; Hsu AAL
    Respir Med; 2016 Sep; 118():1-3. PubMed ID: 27578463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
    Szczeklik A; Nizankowska E; Bochenek G; Nagraba K; Mejza F; Swierczynska M
    Clin Exp Allergy; 2001 Feb; 31(2):219-25. PubMed ID: 11251623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.